Home Business Bio Tech Novartis Acquires Avidity Bios...

Novartis Acquires Avidity Biosciences for $12 Billion in Modern RNA Therapy Deal

Bio Tech

Novartis Buys Avidity Biosciences for $12B Deal - Business Honor

Business Honor
28 October, 2025

The acquisition results in the development of RNA-based therapies and creates new treatments for genetic illnesses.

Novartis AG acquires Avidity Biosciences Inc. for $12 billion, the biggest deal for the business in over a decade, and marks an important step in modern RNA-based therapy. Based on a statement issued, the Swiss pharmaceutical company will pay $72 per share, which is 46% more than Avidity's closing price. This allows Novartis authority over Avidity's experimental medications known as antibody-oligonucleotide conjugates (AOCs).

A new type of treatment focusing on genetic causes of illnesses using synthetic RNA. Avidity is developing therapies for rare neuromuscular conditions like myotonic dystrophy type 1, which leads to weakening in the muscles, and a type of Duchenne muscular dystrophy. The U.S. Food and Drug Administration has previously identified it as "breakthrough therapy."

Two of Avidity's medicines could each produce multibillion-dollar yearly sales before 2030, according to Novartis. Helping the company deal with upcoming generic competition for some of its largest medicines, like the best-selling heart medication Entresto, which will lose its exclusivity later this year. Novartis shares fell roughly 1% in Zurich trading, yet they are still up 16% in 2025. Previously, Avidity's market value was around $6.8 billion, with its shares rising 1.2% to $49.15 in New York.

The action highlights CEO Vas Narasimhan's shift from years of small acquisitions to bigger, more important ones. It comes after Novartis recently acquired Tourmaline Bio, Regulus Therapeutics, and Anthos Therapeutics in a move to improve its pipelines in neurology, immunology, and cardiology. Novartis has made an offer with Avidity that RNA-based precision medications will be capable of treating illnesses at their root. By examining the code of life itself, this partnership might transform how Novartis and modern medicine address disease if the science proves successful.